Tech Company Financing Transactions
STORM Therapeutics Funding Round
STORM Therapeutics closed a $5.4 million Series A funding round on 1/9/2018. Investors included Taiho Ventures.
Transaction Overview
Company Name
Announced On
1/9/2018
Transaction Type
Venture Equity
Amount
$5,430,760
Round
Series A
Investors
Taiho Ventures (Sakae Asanuma)
Proceeds Purpose
Following encouraging progress to date, the financing will enable STORM Therapeutics to expand and accelerate its pipeline, pursue emerging therapeutic opportunities, and build a broader drug discovery platform encompassing new drug targets from additional academic collaborators and its scientific founders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Babraham Research Campus Moneta Building
Cambridge, CB22 3AT
UK
Cambridge, CB22 3AT
UK
Phone
Website
Email Address
Overview
STORM Therapeutics is a University of Cambridge spin-out, translating the groundbreaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Blundy
Chief Scientific Officer
Oliver Rausch
Vice President
Wesley Blackaby
VP - Bus. Development
David Simmons
Browse more venture capital transactions:
Prev: 1/9/2018: SkySpecs venture capital transaction
Next: 1/9/2018: Voatz venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs